An increasing number of studies have been exploring the application of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with NASH/NAFLD, as type 2 diabetes and obesity are so highly associated with this disease [35]. Here, GCG is linked to metabolic dysfunction-associated steatohepatitis.